Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines

Obstetrics and Gynecology

Volumn 125, Issue 4, 2015, Pages 833-842

  Bristow, Robert E ^a   Chang, Jenny ^a   Ziogas, Argyrios ^a   Campos, Belinda ^a   Chavez, Leo R ^a   Anton Culver, Hoda ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; AGED; BLACK PERSON; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE SPECIFIC SURVIVAL; ETHNIC OR RACIAL ASPECTS; FEMALE; FOLLOW UP; HEALTH DISPARITY; HUMAN; INCOME; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; SOCIODEMOGRAPHIC DISPARITY; SURVIVAL TIME; VERY ELDERLY; AFRICAN AMERICAN; ASIAN AMERICAN; CANCER REGISTRY; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; HEALTH CARE DISPARITY; HISPANIC; MEDICARE; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OCEANIC ANCESTRY GROUP; OVARIAN NEOPLASMS; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GUIDELINE ADHERENCE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; MEDICARE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OCEANIC ANCESTRY GROUP; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEER PROGRAM; SOCIAL CLASS; SURVIVAL RATE; UNITED STATES;

EID: 84925398319     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000643     Document Type: Conference Paper

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014;64:9-29.
2. Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY, et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013;105:823-32.
3. Bristow RE, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013;121:1226-34.
4. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol 2013;129:258-64.
5. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011;122:319-23.
6. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcomes for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009;115:4210-7.
7. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111;173-8.
8. Barnholtz-Sloan JS, Tainsky MA, Abrams J, Severson RK, Qureshi F, Jacques SM, et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer 2002;94: 1886-93.
9. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 2010;118:262-7.
10. Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population. Cancer 2010;116:4840-8.
11. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika 1983;70: 41-55.
12. Overview of the SEER program. Available at: http://seer.can-cer.gov/about/overview.html. Retrieved August 20, 2014.
13. Brief description of the SEER-Medicare database. Available at: http://appliedresearch.cancer.gov/seermedicare/overview/. Retrieved August 20, 2014.
14. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States Elderly population. Med Care 2002;40(suppl):IV-3-18.
15. Morgan RJ Jr, Copeland L, Gershenson D, Locker G, McIntosh D, Ozols R, et al. NCCN Ovarian Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996;10(suppl):293-310.
16. Ozols R. Update of the NCCN ovarian cancer practice guidelines. Oncology (Williston Park) 1997;11:95-105.
17. Morgan R, Alvarez RD, Armstrong DK, et al. NCCN practice guidelines for ovarian cancer. Version 2000. Fort Washington (PA): National Comprehensive Cancer Network; 2000.
18. Morgan R, Alvarez RD, Armstrong DK, et al. Ovarian cancer guidelines. Version 1, 2002. Fort Washington (PA): National Comprehensive Cancer Network; 2002.
19. Morgan R, Alvarez RD, Armstrong DK, et al. NCCN ovarian cancer practice guidelines-version 1, 2005. Fort Washington (PA): National Comprehensive Cancer Network; 2005.
20. Morgan R, Alvarez RD, Armstrong DK, et al. NCCN ovarian cancer practice guidelines-version 1, 2007. Fort Washington (PA): National Comprehensive Cancer Network; 2007.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comor-bidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: 373-83.
23. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67.
24. Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in healthcare. Washington, DC: National Academy Press; 2003.
25. Merrill RM, Anderson AE, Merrill JG. Racial/ethnic differences in the use of surgery for ovarian cancer in the United States. Adv Med Sci 2010;55:93-8.
26. Kim S, Dolecek TA, Davis FG. Racial differences in stage at diagnosis and survival from epithelial ovarian cancer: a fundamental cause of disease approach. Soc Sci Med 2010;71:274-81.
27. Parham G, Phillips JL, Hicks ML, Andrews N, Jones WB, Shingleton HM, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer 1997;80:816-26.
28. Howell EA, Egorova N, Hayes MP, Wisnivesky J, Franco R, Bickell N. Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol 2013;122:1025-32.
29. Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian caner in the Medicare population. Gynecol Oncol 2011;122: 100-6.
30. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21:3488-94.
31. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40(suppl):IV-43-8.